Previous studies have demonstrated that the incidence and severity of respiratory virus infections is greater in smokers than in non-smokers, but the mechanisms mediating these responses are currently not well understood. Our preliminary data demonstrate that cultured nasal epithelial cells from smokers are more susceptible to influenza virus infections, shed more virus, and have decreased expression of type 1 interferons. This in vitro model thus provides an important tool to investigate the cellular and molecular basis for enhanced susceptibility to influenza virus seen in smokers. In addition, our preliminary data demonstrate that nasal administration of live attenuated influenza virus (LAIV) offers the possibility of studying influenza virus infections safely in humans in vivo. Using tightly linked human in vitro and in vivo approaches, this proposal is designed to test the hypothesis that chronic exposure to cigarette smoke alters epithelial antiviral and inflammatory responses to influenza virus infection via two potentially related mechanisms: decreased expression of phase II (antioxidant) enzymes and suppression of type 1 interferon (antiviral) pathways. We further hypothesize that upregulation of phase II enzymes via nutritional supplementation with SFN is a potential therapeutic strategy to mitigate these effects.
Specific Aim 1 will use an in vitro model of differentiated human nasal epithelial cells to determine mechanisms that modify influenza-induced antiviral defense responses in smokers, initially focusing on the role of type I IFN antiviral defense responses and the potential role of cigarette smoke-induced gene silencing.
Specific Aim 2 will use our existing protocol of administration of LAIV vaccine as a model for influenza virus infections to confirm mechanisms that mediate enhanced susceptibility to influenza infections in smokers in vivo. LAIV-induced viral replication and antiviral defense responses will be assessed in smokers and non-smokers using endpoints measured in nasal biopsy tissue and lavage fluids. Outcomes within each study cohort will be grouped based on changes in innate immune defense gene expression found in Specific Aim 1.
Specific Aim 3 will use both the in vitro and in vivo models to determine the relationships between antioxidant gene expression, antiviral pathways, and virus-induced inflammation in smokers and non-smokers. We will assess how upregulation of HO-1 as a result of supplementation with SFN can improve key abnormalities in antiviral pathways and inflammatory/immune response changes associated with smokers, as identified in Specific Aims 1 and 2. Data derived from these studies will yield insights into the mechanisms that enhance the susceptibility to influenza virus infections in smokers and explore potential therapeutic interventions using a translational research design.

Public Health Relevance

Susceptibility to and severity of influenza infections is enhanced in smokers, but the mechanisms mediating this effect are largely unknown. We have established human in vitro and in vivo experimental models of influenza infections, which will be applied to determine cellular and molecular mechanisms mediating enhanced susceptibility to influenza virus in smokers and to explore potential therapeutic interventions. Knowledge obtained from these studies can be exploited to develop new therapeutic strategies aimed at mitigating respiratory virus infections and their effects in individuals chronically exposed to tobacco smoke.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Lung Injury, Repair, and Remodeling Study Section (LIRR)
Program Officer
Noel, Patricia
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Schools of Medicine
Chapel Hill
United States
Zip Code
Javaheri, Sogol; Sharma, Ravi K; Bluemke, David A et al. (2017) Association between central sleep apnea and left ventricular structure: the Multi-Ethnic Study of Atherosclerosis. J Sleep Res 26:477-480
McEvoy, John W; Martin, Seth S; Dardari, Zeina A et al. (2017) Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy. Circulation 135:153-165
Baek, Jonggyu; Hirsch, Jana A; Moore, Kari et al. (2017) Statistical Methods to Study Variation in Associations Between Food Store Availability and Body Mass in the Multi-Ethnic Study of Atherosclerosis. Epidemiology 28:403-411
Weng, Lu-Chen; Lunetta, Kathryn L; Müller-Nurasyid, Martina et al. (2017) Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium. Sci Rep 7:11303
Chen, Guanjie; Doumatey, Ayo P; Zhou, Jie et al. (2017) Genome-wide analysis identifies an african-specific variant in SEMA4D associated with body mass index. Obesity (Silver Spring) 25:794-800
Noordam, Raymond; Sitlani, Colleen M; Avery, Christy L et al. (2017) A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and RR and QT intervals: a pharmacogenomics study from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. J Med Genet 54:313-323
Tibuakuu, Martin; Zhao, Di; de Boer, Ian H et al. (2017) Relation of Serum Vitamin D to Risk of Mitral Annular and Aortic Valve Calcium (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol 120:473-478
Seyerle, A A; Sitlani, C M; Noordam, R et al. (2017) Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology. Pharmacogenomics J :
Al Rifai, Mahmoud; DeFilippis, Andrew P; McEvoy, John W et al. (2017) The relationship between smoking intensity and subclinical cardiovascular injury: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 258:119-130
Afshar, Mehdi; Luk, Kevin; Do, Ron et al. (2017) Association of Triglyceride-Related Genetic Variants With Mitral Annular Calcification. J Am Coll Cardiol 69:2941-2948

Showing the most recent 10 out of 287 publications